<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ge LG</submitter><funding>Novo Nordisk Foundation</funding><pagination>212</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11767697</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>30(2)</volume><pubmed_abstract>The overexpression of the epidermal growth factor receptor (EGFR) in certain types of prostate cancers and glioblastoma makes it a promising target for targeted radioligand therapy. In this context, pairing an EGFR-targeting peptide with the emerging theranostic pair comprising the Auger electron emitter cobalt-58m (&lt;sup>58m&lt;/sup>Co) and the Positron Emission Tomography-isotope cobalt-55 (&lt;sup>55&lt;/sup>Co) would be of great interest for creating novel radiopharmaceuticals for prostate cancer and glioblastoma theranostics. In this study, GE11 (YHWYGYTPQNVI) was investigated for its EGFR-targeting potential when conjugated using click chemistry to N1-((triazol-4-yl)methyl)-N1,N2,N2-tris(pyridin-2-ylmethyl)ethane-1,2-diamine (TZTPEN). This chelator is suitable for binding Co&lt;sup>2+&lt;/sup> and C</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pubmed_title>Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.</pubmed_title><pmcid>PMC11767697</pmcid><funding_grant_id>NNF22OC0077099</funding_grant_id><pubmed_authors>Langkjær N</pubmed_authors><pubmed_authors>Danielsen MB</pubmed_authors><pubmed_authors>Nielsen AY</pubmed_authors><pubmed_authors>Skavenborg ML</pubmed_authors><pubmed_authors>McKenzie CJ</pubmed_authors><pubmed_authors>Ge LG</pubmed_authors><pubmed_authors>Thisgaard H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.</name><description>The overexpression of the epidermal growth factor receptor (EGFR) in certain types of prostate cancers and glioblastoma makes it a promising target for targeted radioligand therapy. In this context, pairing an EGFR-targeting peptide with the emerging theranostic pair comprising the Auger electron emitter cobalt-58m (&lt;sup>58m&lt;/sup>Co) and the Positron Emission Tomography-isotope cobalt-55 (&lt;sup>55&lt;/sup>Co) would be of great interest for creating novel radiopharmaceuticals for prostate cancer and glioblastoma theranostics. In this study, GE11 (YHWYGYTPQNVI) was investigated for its EGFR-targeting potential when conjugated using click chemistry to N1-((triazol-4-yl)methyl)-N1,N2,N2-tris(pyridin-2-ylmethyl)ethane-1,2-diamine (TZTPEN). This chelator is suitable for binding Co&lt;sup>2+&lt;/sup> and C</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan</publication><modification>2025-04-04T14:05:37.015Z</modification><creation>2025-04-04T14:05:37.015Z</creation></dates><accession>S-EPMC11767697</accession><cross_references><pubmed>39860082</pubmed><doi>10.3390/molecules30020212</doi></cross_references></HashMap>